Table 5.
Clinical outcome and complications.
| Characteristic | Value |
|---|---|
| Histopathology, n (%) | |
| Non-functioning adenomas | 36 (85.7) |
| Null cell | 22 (52.4) |
| PRL positive | 1 (2.4) |
| GH positive | 1 (2.4) |
| ACTH positive | 1 (2.4) |
| FSH/LH positive | 5 (11.9) |
| TSH positive | 2 (4.8) |
| Plurihormonal positive | 4 (9.5) |
| Functioning adenomas | 6 (14.3) |
| PRL positive | 2 (4.8) |
| GH positive | 1 (2.3) |
| ACTH positive | 1 (2.3) |
| Plurihormonal positive | 2 (4.8) |
| Hormone remission, remission/total | |
| PRL | 1/2 |
| GH | 0/3 |
| ACTH | 1/1 |
| Visual acuity | |
| Improve | 11 (26.2) |
| No change | 23 (54.8) |
| Worsen | 8 (19.0) |
| Visual field | |
| Improve | 7 (16.7) |
| No change | 31 (73.8) |
| Worsen | 4 (9.5) |
| Complications | |
| Hemorrhage | 2 (4.8) |
| Infection | 9 (21.4) |
| Nerve palsies | 16 (38.1) |
| Electrolyte disorder | 20 (47.6) |